C5orf22

Across TCGA pan-cancer cohorts, C5orf22 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C5orf22 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C5orf22 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C5orf22 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where C5orf22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.581	0.288	<.001	41	view →
HNSC	DFS	Quartile	IV	0.549	0.829	.025	8	view →
LUAD	OS	Quartile	III,IV	1.000	0.651	.040	6	view →
GBM	DFS	Median	All	0.486	0.272	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C5orf22–PDAC (DFS)

Open the PDAC breakdown →